Last $1.02 USD
Change Today -0.09 / -8.11%
Volume 67.0K
ENUM On Other Exchanges
Symbol
Exchange
OTC BB
As of 5:20 PM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

enumeral biomedical holdings (ENUM) Snapshot

Open
$1.11
Previous Close
$1.11
Day High
$1.15
Day Low
$1.02
52 Week High
08/5/14 - $2.25
52 Week Low
04/29/14 - $0.02
Market Cap
52.6M
Average Volume 10 Days
27.9K
EPS TTM
--
Shares Outstanding
51.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ENUMERAL BIOMEDICAL HOLDINGS (ENUM)

Related News

No related news articles were found.

enumeral biomedical holdings (ENUM) Related Businessweek News

No Related Businessweek News Found

enumeral biomedical holdings (ENUM) Details

Enumeral Biomedical Holdings, Inc. discovers and develops novel antibody immunotherapies that help immune system to attack diseased cells. It focuses on developing a pipeline of product candidates (immunomodulators) for the treatment of cancer and inflammatory diseases. The company was formerly known as Enumeral Biomedical Corp. and changed its name to Enumeral Biomedical Holdings, Inc. in August 2014. Enumeral Biomedical Holdings, Inc. was founded in 2009 and is based in Cambridge, Massachusetts.

enumeral biomedical holdings (ENUM) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $250.0K
Co-Founder and Executive Chairman
Total Annual Compensation: $200.0K
Vice President of Business Development and Se...
Total Annual Compensation: $171.3K
Compensation as of Fiscal Year 2013.

enumeral biomedical holdings (ENUM) Key Developments

Enumeral Biomedical Holdings, Inc. Appoints Robert L. Van Nostrand to its Board of Directors

Enumeral Biomedical Holdings, Inc. announced that it has appointed Robert L. Van Nostrand to its board of directors. Most recently, Mr. Van Nostrand held senior executive positions with AGI Dermatics and Aureon BioSciences. Mr. Van Nostrand currently serves on the boards of several other publicly traded biotechnology companies, including Metabolix, where he is chairman, Achillion Pharmaceuticals and Intra-Cellular Therapies. Mr. Van Nostrand also serves as the chairman of the audit committee for each of these companies. In addition, Mr. Van Nostrand serves on the board of directors of the Biomedical Research Alliance of New York.

Enumeral Biomedical Holdings, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Month Ended September 30, 2014

Enumeral Biomedical Holdings, Inc. reported unaudited consolidated earnings results for the third quarter and nine month ended September 30, 2014. For the quarter, the company’s revenue was $70,408 against $140,840 a year ago. Loss from operations was $2,151,521 compared to $937,778 a year ago. Net loss before income taxes operations was $8,823,492 compared to $962,302 a year ago. Net loss was $8,823,492 or $0.22 per basic and diluted share compared to $962,302 or $0.26 per basic and diluted share a year ago. For the nine months, the company’s revenue was $121,122 against $341,044 a year ago. Loss from operations was $4,424,024 compared to $2,607,262 a year ago. Net loss before income taxes operations was $11,220,397 compared to $2,690,550 a year ago. Net loss was $11,220,397 or $0.44 per basic and diluted share compared to $2,690,550 or $0.21 per basic and diluted share a year ago.

Enumeral Biomedical Holdings Appoints M. Isabel Chiu as Vice President of Translational and Clinical Sciences

Enumeral Biomedical Holdings, Inc. announced that M. Isabel Chiu, Ph.D., has been appointed Vice President of Translational and Clinical Sciences. Dr. Chiu brings over 20 years of scientific, academic and industry experience in shaping biotechnology programs from research to late-stage development. She is responsible for developing and implementing Enumeral's internal and external translational programs using human patient-derived tissue samples in ex vivo preclinical trials. Dr. Chiu oversees the operational, program management and strategic initiatives to support these goals. Prior to joining Enumeral, Dr. Chiu, served 10 years at AVEO Pharmaceuticals, most recently as Vice President, Translational Research, where she was instrumental in the creation of the company's proprietary "Human Response Platform" and was responsible for applying preclinical insights to guide the company's discovery, development and biomarker programs.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENUM:US $1.02 USD -0.09

ENUM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ENUM.
View Industry Companies
 

Industry Analysis

ENUM

Industry Average

Valuation ENUM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 197.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 179.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENUMERAL BIOMEDICAL HOLDINGS, please visit www.enumeral.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.